Tjoapack and Veratrak launch first live blockchain tool
Secure data sharing across the pharmaceutical industry.
Global contract packaging organisation, Tjoapack, has partnered with UK-based technology company, Veratrak, to establish the use of blockchain across the pharmaceutical industry.
The partnership will include a number of projects that focus on using the properties of blockchain to enable transparent collaboration across multiple pharmaceutical supply chain partners, reducing service lead times, and driving information sharing through a secure digital chain.
The first project, which is due to be rolled out in Q4 2018, will secure and optimise the data sharing processes involved in setting up stock keeping units (SKUs) ready for packaging from product master data to artwork.
Blockchain allows data to be stored as part of an immutable ledger assuring that it cannot be altered or tampered with. Veratrak’s new document collaboration platform uses blockchain technology to allow secure data sharing across the pharmaceutical industry.
Dexter Tjoa, Director Corporate Strategy, Tjoapack said: “This kind of technology will be invaluable when it comes to securing the pharmaceutical supply chain.
“Blockchain is already being explored as a solution to support track and trace programmes which follow physical goods through the supply chain. It could also have huge benefits when it comes to improving data transparency through secure audit logs that are accessible for multiple parties. A tool like the one we’re working on with Veratrak will make collaboration across different companies easier, making the supply chain much more efficient.
“We’re impressed with Veratrak, and are very much looking forward to working closely with their team. Hopefully this will be the first of many projects we collaborate on.”
To date, blockchain technology has been explored by pharmaceutical companies through either proof of concepts (POC) or pilot projects. Veratrak has been built according to GAMP5 guidelines and is compliant with FDA part 11 regulations, making it the first global application of blockchain in a GxP environment working with multiple organisations in the supply chain.
Tjoapack will be the first user of the platform and will use its pharmaceutical expertise to ensure the Veratrak system is tailored to the industry’s challenges and that the solution is tested by an experienced supply chain partner.
Jason Lacombe, CEO, Veratrak said: ”We’re delighted to be working with Tjoapack. We share many of the same values as an organisation, and we're impressed with their forward-thinking mindset. Their committment to contiuously developing and implementing innovative ideas that will improve the supply chain make them an ideal partner for this project.
“Efficient pharmaceutical supply chains are essential for delivering high quality and cost effective healthcare, and this is something that we are both working towards. We hope this will be the start of a successful long-term relationship. Through this partnership, we are building the pharmaceutical supply chain of the future.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance